All In Biotech

Drug Trial Radar · NCT02045862

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,829 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,829

Actual

Start

Mar 17, 2014

Primary completion

Sep 8, 2016

Study completion Sep 8, 2016

Sponsor

Lead sponsor
Astellas Pharma Europe B.V.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jan 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.

Conditions

  • Urinary Bladder Overactive
  • Overactive Bladder
  • Urgency Incontinence
  • Urinary Bladder Diseases\Urologic Diseases

Interventions

  • Solifenacin succinateDrug

    Participants received solifenacin 5 mg orally once a day at the same time each day.

  • MirabegronDrug

    Participants received mirabegron 50 mg orally once a day at the same time each day.

  • Placebo to match solifenacinDrug

    Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.

  • Placebo to match mirabegronDrug

    Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of double-blind study drug up to 30 days after last dose of double-blind study drug (up to 56 weeks)
  2. Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and Week 52
  3. Change From Baseline to EoT in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and Week 52

Locations

251 sites in 32 countries. Site status is shown where the registry gives one.

  • Site US10049

    Mobile, Alabama

  • Site US10112

    Mobile, Alabama

  • Site US10104

    Chandler, Arizona

  • Site US10021

    Phoenix, Arizona

  • Site US10122

    Anaheim, California

  • Site US10082

    Hawaiian Gardens, California

  • Site US10132

    Los Angeles, California

  • Site US10133

    Los Angeles, California

  • Site US10149

    Paramount, California

  • Site US10003

    San Diego, California

  • Site US10106

    Tarzana, California

  • Site US10595

    Valley Village, California

  • Site US10053

    Wheat Ridge, Colorado

  • Site US10060

    Bradenton, Florida

  • Site US10097

    Hialeah, Florida

  • Site US10148

    Hialeah, Florida

  • Site US10153

    Hialeah, Florida

  • Site US10091

    Jupiter, Florida

  • Site US10150

    New Port Richey, Florida

  • Site US10124

    Orlando, Florida

  • Site US10134

    Orlando, Florida

  • Site US10009

    Pembroke Pines, Florida

  • Site US10554

    Plantation, Florida

  • Site US10037

    Alpharetta, Georgia

  • Site US10127

    Roswell, Georgia

  • Site US10120

    Sandy Springs, Georgia

  • Site US10078

    Wichita, Kansas

  • Site US10088

    Lake Charles, Louisiana

  • Site US10025

    Shreveport, Louisiana

  • Site US10558

    Hanover, Maryland

  • Site US10282

    Boston, Massachusetts

  • Site US10114

    Watertown, Massachusetts

  • Site US10110

    Billings, Montana

  • Site US10154

    Missoula, Montana

  • Site US10553

    Lincoln, Nebraska

  • Site US10002

    Englewood, New Jersey

  • Site US10047

    Lawrenceville, New Jersey

  • Site US10011

    Albuquerque, New Mexico

  • Site US10015

    Albuquerque, New Mexico

  • Site US10026

    Garden City, New York

Showing 40 of 251 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.